Mike Olin is listed as an executive officer and director on 2 SEC Form D filings by 1 issuer between May 2017 and Sep 2020: OX2 Therapeutics, Inc. (Minneapolis, MN — biotechnology — 2017–2020; $649K reported sold to 15 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Ben Oehler (2 shared filings), Christopher Moertel (2 shared filings), Jeff Liter (2 shared filings), Andrea Hunt (1 shared filing), Rob Parish (1 shared filing) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Mike. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Mike Olin and found 7 differences: Mike Olin appears on 1 deal that stopped filing before reaching its target; Form D filed 33 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.